Branded Drug Makers Criticize E.U. Deal on Data Protection, Generics
The European Parliament is expected to complete its second reading of the new EU pharmaceutical legislation next month. A final approval by European Union ministers is expected in the first half of 2004, ahead of E.U. enlargement.
While industry groups representing branded drugmakers generally have embraced the efforts to centralize drug evaluations, they are dismayed by a...
To view the full article, register now.